SCHEMBL9890718

SCHEMBL9890718

CNC(=O)Cc1ccccc1-c1ccccc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.49
ALDH1A1 P00352 2/20 0.49
APAF1 O14727 1/20 0.49
TDP2 O95551 1/20 0.49
NSD2 O96028 1/20 0.49
MAPT P10636 1/20 0.49
KDM4C Q9H3R0 1/20 0.49
SAE1 Q9UBE0 1/20 0.49
UBA2 Q9UBT2 1/20 0.49
DPP4 P27487 1/20 0.49
NPSR1 Q6W5P4 1/20 0.47
NPC1 O15118 4/20 0.46
RAB9A P51151 3/20 0.46
MEN1 O00255 1/20 0.44
HTT P42858 1/20 0.44
KCNJ5 P48544 3/20 0.43
KCNJ3 P48549 3/20 0.43
KCNJ6 P48051 1/20 0.42
ERCC1 P07992 1/20 0.41
ERCC4 Q92889 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6393799 0.86 NPC1 (0.56) KMT2AALDH1A1APAF1TDP2NSD2
SCHEMBL9890719 0.84 KMT2A (0.49) KMT2AALDH1A1APAF1TDP2NSD2
SCHEMBL9890711 0.81 HPGD (0.42) KMT2AALDH1A1NPC1RAB9AMEN1
SCHEMBL9642442 0.81 P2RX7 (0.50) KMT2AALDH1A1MAPTNPSR1NPC1
SCHEMBL9890714 0.81 CYP2C19 (0.49) KMT2AMEN1CYP2C19
SCHEMBL2395314 0.80 RAB9A (0.49) KMT2AALDH1A1MAPTRAB9AMEN1
SCHEMBL2397419 0.79 KMT2A (0.51) KMT2AALDH1A1DPP4RAB9A
SCHEMBL9890756 0.79 SUCNR1 (0.46) KMT2AMAPTNPC1RAB9AMEN1
SCHEMBL9890641 0.79 CXCL8 (0.57) ALDH1A1DPP4RAB9ASMN1; SMN2
SCHEMBL2394862 0.77 DPP4 (0.58) KMT2AALDH1A1APAF1TDP2NSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 KMT2A 78/4885ALDH1A1 576/4885APAF1 1932/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 KMT2A 78/4885ALDH1A1 576/4885APAF1 1932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.